595910 Disclosed herein is a carbinol compound of the general formula (I), wherein the variables are defined in the specification, and the use thereof as an LXR regulator for use in the treatment of atherosclerosis, arteriosclerosis, dyslipidemia, hypercholesterolemia, lipid-related diseases, inflammatory diseases that are caused by inflammatory cytokines, skin diseases, diabetes, or Alzheimers disease. Embodiments of the carbinol compound include: (2S,5R)-5-(2,3-dihydrofuro[2,3-c]pyridin-5-yl)-3-(2-(4-(4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)-2-propylphenyl)-2,5-dimethylpiperazin-1-yl)-2-oxoethyl)-5-methylimidazolidine-2,4-dione, (2S,5R,Z)-3-[2-(4-{ 4-[2-(benzyloxy)-1,1,1,3,3,3-hexafluoropropan-2-yl]-2-(prop-1-en-1-yl)phenyl} -2,S-dimethylpiperazin-1-yl)-2-oxoethyl]-S-(2,3-dihydrobenzo[b][1,4]dioxin -6-yl)-S-methylimidazolidine-2,4-dione, and 3-[2-(4-{ 4-[2-(benzyloxy)-1,1,1,3,3,3-hexafluoropropan-2-yl]-2-(prop-1-en-1-yl)phenyl} piperazin-1-yl)-2-oxoethyl]-5-(2,3-dihydro-[1,4]dioxino[2,3-b]pyridin-7-yl)-5-methylimidazolidine-2,4-dione.
